Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective
Ozempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.
The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against lower doses of Novo Nordisk’s medicines.
Continue reading...What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)